|Classification and external resources|
Obstructive sleep apnea
Sleep apnea (or sleep apnoea in British English; //) is a type of sleep disorder characterized by pauses in breathing or instances of shallow or infrequent breathing during sleep. Each pause in breathing, called an apnea, can last from at least ten seconds to several minutes, and may occur 5 to 30 times or more an hour. Similarly, each abnormally shallow breathing event is called a hypopnea. Sleep apnea is often diagnosed with an overnight sleep test called a polysomnogram, or "sleep study".
There are three forms of sleep apnea: central (CSA), obstructive (OSA), and complex or mixed sleep apnea (i.e., a combination of central and obstructive) constituting 0.4%, 84% and 15% of cases respectively. In CSA, breathing is interrupted by a lack of respiratory effort; in OSA, breathing is interrupted by a physical block to airflow despite respiratory effort, and snoring is common.
Regardless of type, an individual with sleep apnea is rarely aware of having difficulty breathing, even upon awakening. Sleep apnea is recognized as a problem by others witnessing the individual during episodes or is suspected because of its effects on the body (sequelae). Symptoms may be present for years (or even decades) without identification, during which time the sufferer may become conditioned to the daytime sleepiness and fatigue associated with significant levels of sleep disturbance.
Sleep apnea affects not only adults but some children as well. As stated by El-Ad, "patients complain about excessive daytime sleepiness (EDS) and impaired alertness". In other words, common effects of sleep apnea include daytime fatigue, a slower reaction time, and vision problems. Moreover, patients are examined using “standard test batteries” in order to further identify parts of the brain that are affected by sleep apnea. Tests have shown that certain parts of the brain cause different effects. The “executive functioning” part of the brain affects the way the patient plans and initiates tasks. Second, the part of the brain that deals with attention causes difficulty in paying attention, working effectively and processing information when in a waking state. Thirdly, the part of the brain that uses memory and learning is also affected. Due to the disruption in daytime cognitive state, behavioral effects are also present. This includes moodiness, belligerence, as well as a decrease in attentiveness and drive. Another symptom of sleep apnea is waking up in sleep paralysis. In severe cases, the fear of sleep due to sleep paralysis can lead to insomnia. These effects become very hard to deal with, thus the development of depression may transpire. There is also evidence that the risk of diabetes among those with moderate or severe sleep apnea is higher. There is also increasing evidence that sleep apnea may also lead to liver function impairment, particularly fatty liver diseases (see steatosis). Finally, because there are many factors that could lead to some of the effects previously listed, some patients are not aware that they suffer from sleep apnea and are either misdiagnosed, or just ignore the symptoms altogether.
- 1 Diagnosis
- 2 Classification
- 3 Treatment
- 4 Epidemiology
- 5 Prognosis
- 6 History
- 7 See also
- 8 References
- 9 External links
The diagnosis of sleep apnea is based on the conjoint evaluation of clinical symptoms (e.g. excessive daytime sleepiness and fatigue) and of the results of a formal sleep study (polysomnography, or reduced channels home based test). The latter aims at establishing an "objective" diagnosis indicator linked to the quantity of apneic events per hour of sleep (Apnea Hypopnea Index(AHI), or Respiratory Disturbance Index (RDI)), associated to a formal threshold, above which a patient is considered as suffering from sleep apnea, and the severity of their sleep apnea can then be quantified. Mild OSA (Obstructive Sleep Apneas) ranges from 5 to 14.9 events per hour of sleep, moderate OSA falls in the range of 15–29.9 events per hour of sleep, and severe OSA would be a patient having over 30 events per hour of sleep.
Nevertheless, due to the number and variability in the actual symptoms and nature of apneic events (e.g., hypopnea vs apnea, central vs obstructive), the variability of patients' physiologies, and the intrinsic imperfections of the experimental setups and methods, this field is opened to debate. Within this context, the definition of an apneic event depends on several factors (e.g. patient's age) and account for this variability through a multi-criteria decision rule described in several, sometimes conflicting, guidelines. One example of a commonly adopted definition of an apnea (for an adult) includes a minimum 10 second interval between breaths, with either a neurological arousal (a 3-second or greater shift in EEG frequency, measured at C3, C4, O1, or O2) or a blood oxygen desaturation of 3–4% or greater, or both arousal and desaturation.
Oximetry, which may be performed overnight in a patient's home, is an easier alternative to formal sleep study (polysomnography). In one study, normal overnight oximetry was very sensitive and so if normal, sleep apnea was unlikely. In addition, home oximetry may be equally effective in guiding prescription for automatically self-adjusting continuous positive airway pressure.
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is the most common category of sleep-disordered breathing. The muscle tone of the body ordinarily relaxes during sleep, and at the level of the throat the human airway is composed of collapsible walls of soft tissue which can obstruct breathing during sleep. Mild occasional sleep apnea, such as many people experience during an upper respiratory infection, may not be important, but chronic severe obstructive sleep apnea requires treatment to prevent low blood oxygen (hypoxemia), sleep deprivation, and other complications.
Individuals with low muscle tone and soft tissue around the airway (e.g., because of obesity) and structural features that give rise to a narrowed airway are at high risk for obstructive sleep apnea. The elderly are more likely to have OSA than young people. Men are more likely to suffer sleep apnea than women and children are, though it is not uncommon in the last two population groups.
The risk of OSA rises with increasing body weight, active smoking and age. In addition, patients with diabetes or "borderline" diabetes have up to three times the risk of having OSA.
Some treatments involve lifestyle changes, such as avoiding alcohol or muscle relaxants, losing weight, and quitting smoking. Many people benefit from sleeping at a 30-degree elevation of the upper body or higher, as if in a recliner. Doing so helps prevent the gravitational collapse of the airway. Lateral positions (sleeping on a side), as opposed to supine positions (sleeping on the back), are also recommended as a treatment for sleep apnea, largely because the gravitational component is smaller in the lateral position. Some people benefit from various kinds of oral appliances to keep the airway open during sleep. Continuous positive airway pressure (CPAP) is the most effective treatment for severe obstructive sleep apnea but oral appliances are considered a first line approach equal to CPAP for mild to moderate sleep apnea according to the AASM parameters of care. There are also surgical procedures to remove and tighten tissue and widen the airway.
Snoring is a common finding in people with this syndrome. Snoring is the turbulent sound of air moving through the back of the mouth, nose, and throat. Although not everyone who snores is experiencing difficulty breathing, snoring in combination with other conditions such as overweight and obesity has been found to be highly predictive of OSA risk. The loudness of the snoring is not indicative of the severity of obstruction, however. If the upper airways are tremendously obstructed, there may not be enough air movement to make much sound. Even the loudest snoring does not mean that an individual has sleep apnea syndrome. The sign that is most suggestive of sleep apneas occurs when snoring stops.
Other indicators include (but are not limited to): hypersomnolence, obesity BMI >30, large neck circumference (16 in (410 mm) in women, 17 in (430 mm) in men), enlarged tonsils and large tongue volume, micrognathia, morning headaches, irritability/mood-swings/depression, learning and/or memory difficulties, and sexual dysfunction.
The term "sleep-disordered breathing" is commonly used in the U.S. to describe the full range of breathing problems during sleep in which not enough air reaches the lungs (hypopnea and apnea). Sleep-disordered breathing is associated with an increased risk of cardiovascular disease, stroke, high blood pressure, arrhythmias, diabetes, and sleep deprived driving accidents. When high blood pressure is caused by OSA, it is distinctive in that, unlike most cases of high blood pressure (so-called essential hypertension), the readings do not drop significantly when the individual is sleeping. Stroke is associated with obstructive sleep apnea.
It has been revealed that people with OSA show tissue loss in brain regions that help store memory, thus linking OSA with memory loss. Using magnetic resonance imaging (MRI), the scientists discovered that sleep apnea patients' mammillary bodies were nearly 20 percent smaller, particularly on the left side. One of the key investigators hypothesized that repeated drops in oxygen lead to the brain injury.
Central sleep apnea
|This article needs additional citations for verification. (May 2010)|
In pure central sleep apnea or Cheyne–Stokes respiration, the brain's respiratory control centers are imbalanced during sleep. Blood levels of carbon dioxide, and the neurological feedback mechanism that monitors them, do not react quickly enough to maintain an even respiratory rate, with the entire system cycling between apnea and hyperpnea, even during wakefulness. The sleeper stops breathing and then starts again. There is no effort made to breathe during the pause in breathing: there are no chest movements and no struggling. After the episode of apnea, breathing may be faster (hyperpnea) for a period of time, a compensatory mechanism to blow off retained waste gases and absorb more oxygen.
While sleeping, a normal individual is "at rest" as far as cardiovascular workload is concerned. Breathing is regular in a healthy person during sleep, and oxygen levels and carbon dioxide levels in the bloodstream stay fairly constant. The respiratory drive is so strong that even conscious efforts to hold one's breath do not overcome it. Any sudden drop in oxygen or excess of carbon dioxide (even if tiny) strongly stimulates the brain's respiratory centers to breathe.
In central sleep apnea, the basic neurological controls for breathing rate malfunction and fail to give the signal to inhale, causing the individual to miss one or more cycles of breathing. If the pause in breathing is long enough, the percentage of oxygen in the circulation will drop to a lower than normal level (hypoxaemia) and the concentration of carbon dioxide will build to a higher than normal level (hypercapnia). In turn, these conditions of hypoxia and hypercapnia will trigger additional effects on the body. Brain cells need constant oxygen to live, and if the level of blood oxygen goes low enough for long enough, the consequences of brain damage and even death will occur. Fortunately, central sleep apnea is more often a chronic condition that causes much milder effects than sudden death. The exact effects of the condition will depend on how severe the apnea is and on the individual characteristics of the person having the apnea. Several examples are discussed below, and more about the nature of the condition is presented in the section on Clinical Details.
In any person, hypoxia and hypercapnia have certain common effects on the body. The heart rate will increase, unless there are such severe co-existing problems with the heart muscle itself or the autonomic nervous system that makes this compensatory increase impossible. The more translucent areas of the body will show a bluish or dusky cast from cyanosis, which is the change in hue that occurs owing to lack of oxygen in the blood ("turning blue"). Overdoses of drugs that are respiratory depressants (such as heroin, and other opiates) kill by damping the activity of the brain's respiratory control centers. In central sleep apnea, the effects of sleep alone can remove the brain's mandate for the body to breathe.
- Normal Respiratory Drive: After exhalation, the blood level of oxygen decreases and that of carbon dioxide increases. Exchange of gases with a lungful of fresh air is necessary to replenish oxygen and rid the bloodstream of built-up carbon dioxide. Oxygen and carbon dioxide receptors in the blood stream (called chemoreceptors) send nerve impulses to the brain, which then signals reflex opening of the larynx (so that the opening between the vocal cords enlarges) and movements of the rib cage muscles and diaphragm. These muscles expand the thorax (chest cavity) so that a partial vacuum is made within the lungs and air rushes in to fill it.
- Physiologic effects of central apnea: During central apneas, the central respiratory drive is absent, and the brain does not respond to changing blood levels of the respiratory gases. No breath is taken despite the normal signals to inhale. The immediate effects of central sleep apnea on the body depend on how long the failure to breathe endures. At worst, central sleep apnea may cause sudden death. Short of death, drops in blood oxygen may trigger seizures, even in the absence of epilepsy. In people with epilepsy, the hypoxia caused by apnea may trigger seizures that had previously been well controlled by medications.[verification needed] In other words, a seizure disorder may become unstable in the presence of sleep apnea. In adults with coronary artery disease, a severe drop in blood oxygen level can cause angina, arrhythmias, or heart attacks (myocardial infarction). Longstanding recurrent episodes of apnea, over months and years, may cause an increase in carbon dioxide levels that can change the pH of the blood enough to cause a metabolic acidosis.
Mixed apnea and complex sleep apnea
Some people with sleep apnea have a combination of both types. When obstructive sleep apnea syndrome is severe and longstanding, episodes of central apnea sometimes develop. The exact mechanism of the loss of central respiratory drive during sleep in OSA is unknown but is most commonly related to acid–base and CO2 feedback malfunctions stemming from heart failure. There is a constellation of diseases and symptoms relating to body mass, cardiovascular, respiratory, and occasionally, neurological dysfunction that have a synergistic effect in sleep-disordered breathing. In some cases, a side effect from the lack of sleep is a mild case of Excessive Daytime Sleepiness (EDS) where the subject has had minimal sleep and this extreme fatigue over time takes its toll on the subject. The presence of central sleep apnea without an obstructive component is a common result of chronic opiate use (or abuse) owing to the characteristic respiratory depression caused by large doses of narcotics.
Complex sleep apnea has recently been described by researchers as a novel presentation of sleep apnea.[dubious ] Patients with complex sleep apnea exhibit OSA, but upon application of positive airway pressure the patient exhibits persistent central sleep apnea. This central apnea is most commonly noted while on CPAP therapy after the obstructive component has been eliminated. This has long been seen in sleep laboratories and has historically been managed either by CPAP or BiLevel therapy. Adaptive servo-ventilation (ASV) modes of therapy have been introduced to attempt to manage this complex sleep apnea. Studies have demonstrated marginally superior performance of the adaptive servo ventilators in treating Cheyne–Stokes breathing; however, no longitudinal studies have yet been published, nor have any results been generated that suggest any differential outcomes versus standard CPAP therapy. At the AARC 2006 in Las Vegas, NV, researchers reported successful treatment of hundreds of patients on ASV therapy; however, these results have not been reported in peer-reviewed publications as of July 2007[update].
It is suggested that transient central apnea produced during CPAP titration (the so-called "complex sleep apnea") is "…transient and self-limited." The central apneas may in fact be secondary to sleep fragmentation during the titration process. As of July 2007[update], there has been no alternate convincing evidence produced that these central sleep apnea events associated with CPAP therapy for obstructive sleep apnea are of any significant pathophysiologic importance.[dated info]
It has been proposed to add dead space to positive airway pressure for treatment of complex sleep-disordered breathing.
Treatment often starts with behavioral therapy. Many patients are told to avoid alcohol, sleeping pills, and other sedatives, which can relax throat muscles, contributing to the collapse of the airway at night. As sleep apnea is inherently worse in the supine position for many patients (positional sleep apnea), sleeping on one's side is often advised.
Possibly owing to changes in pulmonary oxygen stores, sleeping on one's side (as opposed to on one's back) has been found to be helpful for central sleep apnea with Cheyne–Stokes respiration.
Continuous positive airway pressure
For moderate to severe sleep apnea, the most common treatment is the use of a continuous positive airway pressure (CPAP) or automatic positive airway pressure (APAP) device which 'splints' the patient's airway open during sleep by means of a flow of pressurized air into the throat. The patient typically wears a plastic facial mask, which is connected by a flexible tube to a small bedside CPAP machine. The CPAP machine generates the required air pressure to keep the patient's airways open during sleep. While pure CPAP machines require one to input a desired pressure (usually determined in an overnight sleep study), an APAP machine will automatically titrate the air pressure as needed to minimize apneas and hypopneas. Advanced models may warm or humidify the air and monitor the patient's breathing to ensure proper treatment.
Although CPAP therapy is extremely effective in reducing apneas and less expensive than other treatments, some patients find it extremely uncomfortable. Many patients refuse to continue the therapy or fail to use their CPAP machines on a nightly basis, especially in the long term. One way to ensure CPAP therapy remains comfortable and effective for patients is to carefully consider the right CPAP face mask to be used. CPAP masks come in different shapes, sizes and materials to ensure effective treatment for obstructive sleep apnea. It is important to select the right mask to fit each patient.
It is not clear that CPAP reduces hypertension or cardiovascular events in patients who do not have daytime sleepiness; however, the lack of benefit may be partly due to noncompliance with therapy.
There is limited evidence for medication but acetazolamide "may be considered" for the treatment of central sleep apnea; it also found that zolpidem and triazolam may be considered for the treatment of central sleep apnea, but "only if the patient does not have underlying risk factors for respiratory depression". Low doses of oxygen are also used as a treatment for hypoxia but are discouraged due to side effects.
General dentists can fabricate an oral appliance. The oral appliance, called a mandibular advancement splint, is a custom-made mouthpiece that shifts the lower jaw forward and opens the bite slightly, which opens up the airway. Oral appliance therapy (OAT) is usually successful in patients with mild to moderate obstructive sleep apnea. OAT is a relatively new treatment option for sleep apnea in the United States, but it is much more common in Canada and Europe.
Several surgical procedures (sleep surgery) are used to treat sleep apnea, although they are normally a second line of treatment for those who reject CPAP treatment or are not helped by it. Surgical treatment for obstructive sleep apnea needs to be individualized to address all anatomical areas of obstruction. Often, correction of the nasal passages needs to be performed in addition to correction of the oropharynx passage. Septoplasty and turbinate surgery may improve the nasal airway. Tonsillectomy and uvulopalatopharyngoplasty (UPPP or UP3) are available to address pharyngeal obstruction. Base-of-tongue advancement by means of advancing the genial tubercle of the mandible may help with the lower pharynx. Many other treatments are available, including hyoid bone myotomy and suspension and various radiofrequency
Other surgery options may attempt to shrink or stiffen excess tissue in the mouth or throat; procedures done at either a doctor's office or a hospital. Small shots or other treatments, sometimes in a series, are used for shrinkage, while the insertion of a small piece of stiff plastic is used in the case of surgery whose goal is to stiffen tissues.
The Pillar Procedure is a minimally invasive treatment for snoring and obstructive sleep apnea. This procedure was FDA indicated in 2004. During this procedure, three to six or more Dacron (the material used in permanent sutures) strips are inserted into the soft palate, using a modified syringe and local anesthetic. While the procedure was initially approved for the insertion of three "pillars" into the soft palate, it was found that there was a significant dosage response to more pillars, with appropriate candidates. After this brief and virtually painless outpatient operation, which usually lasts no more than 30 minutes, the soft palate is more rigid and snoring and sleep apnea can be reduced. This procedure addresses one of the most common causes of snoring and sleep apnea — vibration or collapse of the soft palate (the soft part of the roof of the mouth). If there are other factors contributing to snoring or sleep apnea, such as the nasal airway or an enlarged tongue, it will likely need to be combined with other treatments to be more effective.
The Stanford Center for Excellence in Sleep Disorders Medicine achieved a 95% cure rate of sleep apnea patients by surgery. Maxillomandibular advancement (MMA) is considered the most effective surgery for sleep apnea patients, because it increases the posterior airway space (PAS). The main benefit of the operation is that the oxygen saturation in the arterial blood increases. In a study published in 2008, 93.3.% of surgery patients achieved an adequate quality of life based on the Functional Outcomes of Sleep Questionnaire (FOSQ). Surgery led to a significant increase in general productivity, social outcome, activity level, vigilance, intimacy, and intercourse. Overall risks of MMA surgery are low: The Stanford University Sleep Disorders Center found 4 failures in a series of 177 patients, or about one out of 44 patients. However, health professionals are often unsure as to who should be referred for surgery and when to do so: some factors in referral may include failed use of CPAP or device use; anatomy which favors rather than impeding surgery; or significant craniofacial abnormalities which hinder device use. Maxillomandibular advancement surgery is often combined with Genioglossus Advancement, as both are skeletal surgeries for sleep apnea.
Several inpatient and outpatient procedures use sedation. Many drugs and agents used during surgery to relieve pain and to depress consciousness remain in the body at low amounts for hours or even days afterwards. In an individual with either central, obstructive or mixed sleep apnea, these low doses may be enough to cause life-threatening irregularities in breathing or collapses in a patient’s airways. Use of analgesics and sedatives in these patients postoperatively should therefore be minimized or avoided.
Surgery on the mouth and throat, as well as dental surgery and procedures, can result in postoperative swelling of the lining of the mouth and other areas that affect the airway. Even when the surgical procedure is designed to improve the airway, such as tonsillectomy and adenoidectomy or tongue reduction, swelling may negate some of the effects in the immediate postoperative period. Once the swelling resolves and the palate becomes tightened by postoperative scarring, however, the full benefit of the surgery may be noticed.
A sleep apnea patient undergoing any medical treatment must make sure his or her doctor and anesthetist are informed about the sleep apnea. Alternative and emergency procedures may be necessary to maintain the airway of sleep apnea patients. If an individual suspects he or she may have sleep apnea, communication with their doctor about possible preprocedure screening may be in order.
Other studies have also suggested that strengthening the muscles around the upper airway may combat sleep apnea. A 2001 study investigated changes after Tongue Muscle Training (ZMT®) in respiratory parameters during night-time sleep of patients with increased respiratory disease index. 40 sleep apnea patients, which up to this time had been treated with nCPAP, underwent electrostimulation of the suprahyoidal musculature for 5 weeks with a special EMS-device. The apnea, hypopnea and desaturation indexes were reduced in 26 of the 40 patients (65%) by an average of approximately one half. A 2005 study in the British Medical Journal found that learning and practicing the didgeridoo helped reduce snoring and sleep apnea as well as daytime sleepiness. This appears to work by strengthening muscles in the upper airway, thus reducing their tendency to collapse during sleep. A 2009 study published in the American Journal of Respiratory and Clinical Care Medicine found that patients who practiced a series of tongue and throat exercises for 30 minutes a day showed a marked decline in sleep apnea symptoms after three months. Patients experienced an average of 39% fewer apnea episodes after successfully completing the treatments. 
Cannabis derivatives have also been studied in the treatment of sleep apnea. A 2002 study found that orally administered THC was able to stabilize respiration in rats and bulldogs during all sleep stages, decreasing apnea indexes during NREM and REM sleep stages by 42% and 58% respectively. A 2013 proof of concept trial found that dronabinol (synthetic THC) was able to reduce apnea indexes by 32% on average in the 17 human subjects that were studied. Lead study author David Carley subsequently received a $5 million grant from the National Institutes of Health (NIH) to conduct a Phase II clinical trial.
The Wisconsin Sleep Cohort Study estimated in 1993 that roughly one in every 15 Americans was affected by at least moderate sleep apnea. It also estimated that in middle-age as many as nine percent of women and 24 percent of men were affected, undiagnosed and untreated.
The costs of untreated sleep apnea reach further than just health issues. It is estimated that in the U.S. the average untreated sleep apnea patient's annual health care costs $1,336 more than an individual without sleep apnea. This may cause $3.4 billion/year in additional medical costs. Whether medical cost savings occur with treatment of sleep apnea remains to be determined.
A 2012 study has shown that hypoxia (an inadequate supply of oxygen) that characterizes sleep apnea promotes angiogenesis which increase vascular and tumor growth, which in turn results in a 4.8 times higher incidence of cancer mortality.
The clinical picture of this condition has long been recognized as a character trait, without an understanding of the disease process. The term "Pickwickian syndrome" that is sometimes used for the syndrome was coined by the famous early 20th century physician, William Osler, who must have been a reader of Charles Dickens. The description of Joe, "the fat boy" in Dickens's novel The Pickwick Papers, is an accurate clinical picture of an adult with obstructive sleep apnea syndrome.
The early reports of obstructive sleep apnea in the medical literature described individuals who were very severely affected, often presenting with severe hypoxemia, hypercapnia and congestive heart failure.
The management of obstructive sleep apnea was revolutionized with the introduction of continuous positive airway pressure (CPAP), first described in 1981 by Colin Sullivan and associates in Sydney, Australia. The first models were bulky and noisy, but the design was rapidly improved and by the late 1980s CPAP was widely adopted. The availability of an effective treatment stimulated an aggressive search for affected individuals and led to the establishment of hundreds of specialized clinics dedicated to the diagnosis and treatment of sleep disorders. Though many types of sleep problems are recognized, the vast majority of patients attending these centers have sleep-disordered breathing.
- "Sleep Apnea: What Is Sleep Apnea?". NHLBI: Health Information for the Public. U.S. Department of Health and Human Services. May 2009. Retrieved 2010-08-05.
- Morgenthaler TI, Kagramanov V, Hanak V, Decker PA (September 2006). "Complex sleep apnea syndrome: is it a unique clinical syndrome?". Sleep 29 (9): 1203–9. PMID 17040008. Lay summary – Science Daily (September 4, 2006).
- "Sleep Apnea: Key Points". NHLBI: Health Information for the Public. U.S. Department of Health and Human Services.
- El-Ad, Baruch; Lavie, Peretz (2005). "Effect of sleep apnea on cognition and mood". International Review of Psychiatry 17 (4): 577–582. doi:10.1080/09540260500104508.
- Aloia, M.S.; Sweet, L.H.; Jerskey, B.A.; Zimmerman, M.; Arnedt, T.J.; Millman, R.P. (2009). "Treatment effects on brain activity during a working memory task in obstructive sleep apnea". Journal of Sleep Research (Wiley-Blackwell) 18 (4): 404–410. doi:10.1111/j.1365-2869.2009.00755.x. Retrieved 17 February 2012.
- Sculthorpe LD, Douglass AB (July 2010). "Sleep pathologies in depression and the clinical utility of polysomnography". Can J Psychiatry 55 (7): 413–21. PMID 20704768.
- Morgenstern, Michael; Wang Janice. "Obstructive Sleep Apnea: An Unexpected Cause of Insulin Resistance and Diabetes". Endocrinology and Metabolism Clinics of North America 43 (1): 187–204. doi:10.1016/j.ecl.2013.09.002.
- MH Ahmed, CD Byrne (2010). "Obstructive sleep apnea syndrome and fatty liver: association or causal link?". World J Gastroenterol 16 (34): 4243–52. doi:10.3748/wjg.v16.i34.4243. PMC 2937104. PMID 20818807.
- H Singh, R Pollock, J Uhanova, M Kryger, K Hawkins, GY Minuk (2005). "Symptoms of Obstructive Sleep Apnea in Patients with Nonalcoholic Fatty Liver Disease". Digestive Diseases and Sciences 50 (12): 2338–2343. doi:10.1007/s10620-005-3058-y.
- F Tanne, F Gagnadoux, O Chazouilleres, B Fleury, D Wendum, E Lasnier, B Labeau, R Poupon, L Serfaty (2005). "Chronic Liver Injury During Obstructive Sleep Apnea". Hepatology 41 (6): 1290–1296. doi:10.1002/hep.20725.
- Redline S, Budhiraja R, Kapur V et al. (2007). "Reliability and validity of respiratory event measurement and scoring". J Clin Sleep Med 3 (2): 169–200. PMID 17557426.
- AASM Task Force (1999). "Sleep–Related Breathing Disorders in Adults – Recommendations for Syndrome Definition and Measurement Techniques in Clinical Research". SLEEP 22 (5): 667–689. PMID 10450601.
- Ruehland WR, Rochford PD, O'Donoghue FJ, Pierce RJ, Singh P, Thornton AT (2009). "The new aasm criteria for scoring hypopneas: Impact on the apnea hypopnea index". SLEEP 32 (2): 150–157. PMC 2635578. PMID 19238801.
- Sériès, F.; Marc, I.; Cormier, Y.; La Forge, J. (1993). "Utility of nocturnal home oximetry for case finding in patients with suspected sleep apnea hypopnea syndrome". Annals of internal medicine 119 (6): 449–453. PMID 8357109.
- Whitelaw WA, Brant RF, Flemons WW (2005). "Clinical usefulness of home oximetry compared with polysomnography for assessment of sleep apnea.". Am J Respir Crit Care Med 171 (2): 188–93. doi:10.1164/rccm.200310-1360OC. PMID 15486338. Review in: ACP J Club. 2005 Jul-Aug;143(1):21
- "Sleep Apnea: Who Is At Risk for Sleep Apnea?". NHLBI: Health Information for the Public. U.S. Department of Health and Human Services.
- Neill AM, Angus SM, Sajkov D, McEvoy RD (January 1997). "Effects of sleep posture on upper airway stability in patients with obstructive sleep apnea". American Journal of Respiratory and Critical Care Medicine 155 (1): 199–204. doi:10.1164/ajrccm.155.1.9001312. PMID 9001312.
- Xiheng, Guo; Chen, Wang; Hongyu, Zhang; Weimin, Kong; Li, An; Li, Liu; Xinzhi, Weng (2003). The Study Of The Influence Of Sleep Position On Sleep Apnea. Cardinal Health.[dead link]
- Loord H, Hultcrantz E (August 2007). "Positioner--a method for preventing sleep apnea". Acta Oto-laryngologica 127 (8): 861–8. doi:10.1080/00016480601089390. PMID 17762999.
- Szollosi I, Roebuck T, Thompson B, Naughton MT (August 2006). "Lateral sleeping position reduces severity of central sleep apnea / Cheyne–Stokes respiration". Sleep 29 (8): 1045–51. PMID 16944673.
- Vennelle M, White S, Riha RL, Mackay TW, Engleman HM, Douglas NJ (February 2010). "Randomized controlled trial of variable-pressure versus fixed-pressure continuous positive airway pressure (CPAP) treatment for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS)". Sleep 33 (2): 267–71. PMC 2817914. PMID 20175411.
- Morris LG, Kleinberger A, Lee KC, Liberatore LA, Burschtin O (November 2008). "Rapid risk stratification for obstructive sleep apnea, based on snoring severity and body mass index". Otolaryngology-Head and Neck Surgery 139 (5): 615–8. doi:10.1016/j.otohns.2008.08.026. PMID 18984252.
- Yan-fang S, Yu-ping W (August 2009). "Sleep-disordered breathing: impact on functional outcome of ischemic stroke patients". Sleep Medicine 10 (7): 717–9. doi:10.1016/j.sleep.2008.08.006. PMID 19168390.
- Bixler EO, Vgontzas AN, Lin HM, et al. (November 2008). "Blood pressure associated with sleep-disordered breathing in a population sample of children". Hypertension 52 (5): 841–6. doi:10.1161/HYPERTENSIONAHA.108.116756. PMID 18838624.
- Leung RS (2009). "Sleep-disordered breathing: autonomic mechanisms and arrhythmias". Progress in Cardiovascular Diseases 51 (4): 324–38. doi:10.1016/j.pcad.2008.06.002. PMID 19110134.
- Silverberg DS, Iaina A, Oksenberg A (January 2002). "Treating obstructive sleep apnea improves essential hypertension and life". American Family Physician 65 (2): 229–36. PMID 11820487.
- Grigg-Damberger M (February 2006). "Why a polysomnogram should become part of the diagnostic evaluation of stroke and transient ischemic attack". Journal of Clinical Neurophysiology 23 (1): 21–38. doi:10.1097/01.wnp.0000201077.44102.80. PMID 16514349.
- Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V (November 2005). "Obstructive sleep apnea as a risk factor for stroke and death". The New England Journal of Medicine 353 (19): 2034–41. doi:10.1056/NEJMoa043104. PMID 16282178.
- Kumar R, Birrer BV, Macey PM, et al. (June 2008). "Reduced mammillary body volume in patients with obstructive sleep apnea". Neuroscience Letters 438 (3): 330–4. doi:10.1016/j.neulet.2008.04.071. PMID 18486338.
- Kumar R, Birrer BV, Macey PM, et al. (June 2008). "Reduced mammillary body volume in patients with obstructive sleep apnea". Neuroscience Letters 438 (3): 330–4. doi:10.1016/j.neulet.2008.04.071. PMID 18486338. Lay summary – Newswise (June 6, 2008).
- Dernaika T, Tawk M, Nazir S, Younis W, Kinasewitz GT (July 2007). "The significance and outcome of continuous positive airway pressure-related central sleep apnea during split-night sleep studies". Chest 132 (1): 81–7. doi:10.1378/chest.06-2562. PMID 17475636.
- Thomas RJ (March 2005). "Effect of added dead space to positive airway pressure for treatment of complex sleep-disordered breathing". Sleep Medicine 6 (2): 177–8. doi:10.1016/j.sleep.2004.11.004. PMID 15716223.
- "How Is Sleep Apnea Treated?". National Heart, Lung, and Blood Institute.
- Aurora RN et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses Sleep. 2012 Jan 1;35(1):17-40.
- General Information about Sleep Apnea Machines
- Hsu AA, Lo C (December 2003). "Continuous positive airway pressure therapy in sleep apnoea". Respirology 8 (4): 447–54. doi:10.1046/j.1440-1843.2003.00494.x. PMID 14708553.
- Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al. (May 2012). "Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial". JAMA 307 (20): 2161–8. doi:10.1001/jama.2012.4366. PMID 22618923.
- "Sleep Apnea". Diagnosis Dictionary. Psychology Today.
- Mayos M, Hernández Plaza L, Farré A, Mota S, Sanchis J (February 2001). "[The effect of nocturnal oxygen therapy in patients with sleep apnea syndrome and chronic airflow limitation]". Archivos de Bronconeumología (in Spanish) 37 (2): 65–8. doi:10.1016/S0300-2896(01)75016-8. PMID 11181239.
- Breitenbücher A, Keller-Wossidlo H, Keller R (November 1989). "[Transtracheal oxygen therapy in obstructive sleep apnea syndrome]". Schweizerische Medizinische Wochenschrift (in German) 119 (46): 1638–41. PMID 2609134.
- Machado MA, Juliano L, Taga M, de Carvalho LB, do Prado LB, do Prado GF (December 2007). "Titratable mandibular repositioner appliances for obstructive sleep apnea syndrome: are they an option?". Sleep & Breathing 11 (4): 225–31. doi:10.1007/s11325-007-0109-y. PMID 17440760.
- Li KK, Riley RW, Powell NB, Troell R, Guilleminault C (November 1999). "Overview of phase II surgery for obstructive sleep apnea syndrome". Ear, Nose, & Throat Journal 78 (11): 851, 854–7. PMID 10581838.
- Prinsell JR (November 2002). "Maxillomandibular advancement surgery for obstructive sleep apnea syndrome". Journal of the American Dental Association 133 (11): 1489–97; quiz 1539–40. doi:10.14219/jada.archive.2002.0079. PMID 12462692.
- Lye KW, Waite PD, Meara D, Wang D (May 2008). "Quality of life evaluation of maxillomandibular advancement surgery for treatment of obstructive sleep apnea". Journal of Oral and Maxillofacial Surgery 66 (5): 968–72. doi:10.1016/j.joms.2007.11.031. PMID 18423288.
- Li KK, Powell NB, Riley RW, Troell RJ, Guilleminault C (2000). "Long-Term Results of Maxillomandibular Advancement Surgery". Sleep & Breathing 4 (3): 137–140. doi:10.1007/s11325-000-0137-3. PMID 11868133.
- MacKay, Stuart (June 2011). "Treatments for snoring in adults". Australian Prescriber (34): 77–79.
- Johnson, T. Scott; Broughton, William A.; Halberstadt, Jerry (2003). Sleep Apnea – The Phantom of the Night: Overcome Sleep Apnea Syndrome and Win Your Hidden Struggle to Breathe, Sleep, and Live. New Technology Publishing. ISBN 978-1-882431-05-2.[page needed]
- National Heart, Lung, and Blood Institute (2012). "What is Sleep Apnea?". National Institutes of Health. Retrieved 15 February 2013.
- Gessmann HW et al: The Tongue Muscle Training (ZMT®) in nCPAP Patients with Obstructive Sleep Apnea Syndrome (OSAS). PIB Publisher Duisburg, Germany 2001
- Puhan MA, Suarez A, Lo Cascio C, Zahn A, Heitz M, Braendli O (February 2006). "Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial". BMJ 332 (7536): 266–70. doi:10.1136/bmj.38705.470590.55. PMC 1360393. PMID 16377643.
- Guimarães KC, Drager LF, Genta PR, Marcondes BF, Lorenzi-Filho G (May 2009). "Effects of oropharyngeal exercises on patients with moderate obstructive sleep apnea syndrome". Am. J. Respir. Crit. Care Med. 179 (10): 962–6. doi:10.1164/rccm.200806-981OC. PMID 19234106.
- Carley DW, Paviovic S, Janelidze M, Radulovacki M (June 2002). "Functional role for cannabinoids in respiratory stability during sleep.". Sleep 25 (4): 391–8. PMID 12071539.
- Prasad B, Radulovacki MG, Carley DW (Jan 2013). "Proof of concept trial of dronabinol in obstructive sleep apnea.". Front Psychiatry 4 (1). doi:10.3389/fpsyt.2013.00001. PMC 3550518. PMID 23346060.
- "Cortex Pharmaceuticals and Pier Pharmaceuticals Consummate Merger". BusinessWire.com. 14 August 2012. Retrieved 7 August 2013.
- Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (April 1993). "The occurrence of sleep-disordered breathing among middle-aged adults". The New England Journal of Medicine 328 (17): 1230–5. doi:10.1056/NEJM199304293281704. PMID 8464434.
- Lee W, Nagubadi S, Kryger MH, Mokhlesi B (June 1, 2008). "Epidemiology of obstructive sleep apnea: a population-based perspective". Expert Rev Respir Med 2 (3): 349–64. doi:10.1586/174763184.108.40.2069. PMC 2727690. PMID 19690624.
- Young T, Peppard PE, Gottlieb DJ (May 2002). "Epidemiology of obstructive sleep apnea: a population health perspective". American Journal of Respiratory and Critical Care Medicine 165 (9): 1217–39. doi:10.1164/rccm.2109080. PMID 11991871.
- Kapur V, Blough DK, Sandblom RE, et al. (September 1999). "The medical cost of undiagnosed sleep apnea". Sleep 22 (6): 749–55. PMID 10505820.
- torontosun.com – Study links sleep apnea with higher cancer deaths, 2012-05-20
- Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farré R (May 2012). "Sleep disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study". Am J Respir Crit Care Med. doi:10.1164/rccm.201201-0130OC. PMID 22610391.
- "Sleep apnea ups cancer death risk five-fold". The Times Of India. 2012-05-27. Retrieved 27 May 2012.
- Sullivan CE, Issa FG, Berthon-Jones M, Eves L. (April 1981). "Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares". Lancet 1 (8225): 862–5. doi:10.1016/S0140-6736(81)92140-1. PMID 6112294.